Tag: DCB
TRANSFORM II study of sirolimus DCB completes patient enrolment
Enrolment has been completed in the TRANSFORM II randomised controlled trial, comparing the MagicTou...
Trial of DCB and scaffold technologies enrols first CTO-PCI patients
Biotronik has announced the enrolment of the first patient in the Leave Nothing Behind-trial, which ...
CRT 2025: AGENT IDE trial results “consistent” out to two years using DCB in ISR
Consistent results have been seen out to two years in the AGENT investigational device exemption...
CRT 2025: SCAAR analysis shows comparable outcomes between Prevail and other DCBs
A real-world study of the Prevail (Medtronic) drug-coated balloon (DCB), comparing the device to...
DCB Days examines the new momentum in DCB-PCI
“This technique is here to stay,” says Raban Jeger (Basel, Switzerland) reflecting on the growin...
Medtronic commences Prevail Global study as it seeks coronary DCB approvals in USA and Japan
Medtronic has announced that the first patient has been enrolled in its pivotal trial of the Prevail...
Advertorial: DCB Days showcases new momentum in drug-coated balloon PCI
This advertorial is sponsored by B Braun Melsungen AG
Drug-coated balloons (DCBs) are building to...
Bruno Scheller
Despite a complicated early path into medicine, which was shaped by a major tragedy, Bruno Scheller ...
TCT 2024: One-year data from SIRONA trial show similar results for sirolimus versus paclitaxel DCB
Data from the prospective, multicentre, investigator-initiated SIRONA randomised clinical trial ...
First-in-human results for dual-drug therapy DCB released
Advanced NanoTherapies has announced positive results from its first-in-human (FIH) trial evalua...
Medtronic’s Prevail DCB to be studied in US IDE trial
Medtronic has received approval of a US Food and Drug Administration (FDA) investigational device ex...
ESC 2024: Chronic coronary syndrome guidelines clarify role of revascularisation and strengthen imaging recommendations
The European Society of Cardiology (ESC) has issued updated guidelines on the management of chronic ...
How using DCBs can “open up a new world” for PCI
Early exposure to the use of drug-coated balloons (DCBs) for percutaneous coronary intervention ...
CX 2024: Paclitaxel device restrictions “did cause harm”
“Unfortunately, we are doing worse for our patients today,” were the sobering words of Eric Sece...
Boston Scientific’s Agent DCB gains first US FDA coronary approval
Boston Scientific has announced that it has received US Food and Drug Administration (FDA) approval ...
Latest-generation DCBs “change thinking” on treatment of coronary artery disease
Interventional cardiologists need to have a range of approaches and devices in their toolbox to t...
EuroPCR 2023: Biolimus-coated balloon fails to match paclitaxel for in-stent restenosis
Results of the first study of a first-generation drug-coated balloon (DCB) with a biolimus coati...
ADVERTORIAL: Ready for the primetime? The future role of drug-coated balloons in PCI
This advertorial is sponsored by B Braun Melsungen AG
“The evolution of PCI has always been a co...
Important to utilise DCBs with strongest possible data behind them
NOTE: This video is ONLY available to watch in selected countries and geographies
Tuomas Ri...
Breakthrough device designation granted for SirPlux Duo coronary DCB in small vessels
Advanced NanoTherapies has been granted US Food and Drug Administration (FDA) breakthrough devic...
Enrolment completed in TRANSFORM 1 trial of MagicTouch DCB
Concept Medical has announced the successful completion of the TRANSFORM 1 RCT. The randomised c...
First patient enrolled in TRANSFORM II study of sirolimus-coated balloon
The first patient has been enrolled in the TRANSFORM II randomised controlled trial assessing th...
Cardiovascular Systems and Chansu Vascular Technologies partner to develop new everolimus DCBs
Cardiovascular Systems (CSI) has partnered with Chansu Vascular Technologies (CVT) to develop no...
Paclitaxel coated balloons have lower risk of mortality in coronary arteries at three years than control treatments
Paclitaxel drug coated balloons (DCB) for percutaneous treatment of coronary artery disease (CAD...
Customising therapy in femoropopliteal revascularisation
Gary Ansel (Columbus, USA) tells Vascular News at VEITHSymposium 2018 about how drug-based ther...
Meta-analysis finds a higher risk of death in the long term when paclitaxel-coated devices are used in the leg
New data, just published in the Journal of the American Heart Association (JAHA), suggest that t...
